Use of the Novel Therapeutic Agent Miltefosine for the Treatment of Primary Amebic Meningoencephalitis: Report of 1 Fatal and 1 Surviving Case: Table 1.
Open Access
- 17 December 2015
- journal article
- case report
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 62 (6) , 774-776
Abstract
Primary amebic meningoencephalitis (PAM) is a fulminant central nervous system infection caused by the thermophilic free-living ameba Naegleria fowleri. Few survivals have been documented and adequate treatment is lacking. We report 2 PAM cases, 1 fatal and 1 surviving, treated with the novel antiparasitic agent miltefosine.Keywords
This publication has 11 references indexed in Scilit:
- Successful Treatment of an Adolescent With Naegleria fowleri Primary Amebic MeningoencephalitisPediatrics, 2015
- The First Association of a Primary Amebic Meningoencephalitis Death With Culturable Naegleria fowleri in Tap Water From a US Treated Public Drinking Water SystemClinical Infectious Diseases, 2015
- Diagnosis, Clinical Course, and Treatment of Primary Amoebic Meningoencephalitis in the United States, 1937-2013Journal of the Pediatric Infectious Diseases Society, 2014
- Primary Amebic Meningoencephalitis Associated with Ritual Nasal Rinsing — St. Thomas, U.S. Virgin Islands, 20122013
- Investigational Drug Available Directly from CDC for the Treatment of Infections with Free-Living Amebae2013
- Primary Amebic Meningoencephalitis Deaths Associated With Sinus Irrigation Using Contaminated Tap WaterClinical Infectious Diseases, 2012
- Successful Treatment ofBalamuthia mandrillarisAmoebic Infection with Extensive Neurological and Cutaneous InvolvementClinical Infectious Diseases, 2010
- Oral Miltefosine for Indian Visceral LeishmaniasisNew England Journal of Medicine, 2002
- Successful Treatment of Primary Amebic MeningoencephalitisNew England Journal of Medicine, 1982
- PRIMARY AMŒBIC MENINGOENCEPHALITISThe Lancet, 1972